
Cardiovascular Health
Latest News

Latest Videos

Shorts

Podcasts
CME Content
More News

Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
The agent is to be used alongside diet adjustments in adult patients.

Leonard Egede explains why PHQ-9 screening belongs in every cardio-kidney-metabolic (CKM) syndrome risk assessment—and how community pharmacists can reach patients the formal system misses.

TIMI Study Group investigators presented new VESALIUS-CV data showing that intensive LDL-C lowering with evolocumab reduces major cardiovascular events, reinforcing the "lower is better, earlier is better" approach to lipid management.

The landscape of cardiovascular prevention is shifting from a focus on surrogate biomarkers to a more granular, image-based assessment of actual disease burden.

New 2026 lipid guidelines push earlier screening, PREVENT risk scoring, and tougher LDL/ApoB targets with expanded nonstatin options.

Although polypharmacy is common in older adults and may increase the risk of adverse events and drug-drug interactions, statin therapy may continue to provide benefit in patients older than 75 years.

Craig Beavers, PharmD, shares his initial thoughts on the new 2026 CKM guidelines, which highlights a landmark shift in cardiovascular care.

Joseph Saseen, PharmD, discusses how pharmacists can overcome therapeutic inertia and sequence nonstatin therapies to help patients reach individualized LDL-C goals.

Although evidence supports safety of apixaban and rivaroxaban relative to warfarin, researchers had not directly compared their bleeding risk until last year.

A cross-sectional analysis of nearly 30,000 US adults found that economic instability, food insecurity, limited education, and poor social context each independently elevated the odds of advanced cardiovascular-kidney-metabolic (CKD) syndrome—but not equally across all groups.

What's Making Headlines in Cardiovascular Care: A Pharmacist's Breakdown of the Latest Breakthroughs
Craig Beavers highlights 3 major developments in cardiovascular and cardiometabolic medicine that pharmacists should have on their radar.

Emerging data support less intensive antithrombotic strategies for LVADs that could reduce bleeding complications without compromising thromboembolic protection.

A large analysis found that measurable declines in processing speed, global cognition, and executive function began up to 8 years before a cardiovascular event.

The FDA approved baxdrostat based on meaningfully positive results from the phase 3 BaxHTN trial.

Darren Triller, PharmD, walks through the relative ease and impact of each of the 5 ADAPT priority areas, makes the case for dashboard-driven population health management.

Clinical pharmacists Andrew Willeford and Laura Velazquez explore the paradigm shift in oHCM management, highlighting best practices for pharmacist-led clinical workflows in health-system practice.

Securing executive buy-in, building multidisciplinary coalitions, and targeting inappropriate antiplatelet use are among the most critical steps in implementing antithrombotic stewardship programs.

Darren Triller, PharmD, makes the case for system-level solutions over individual clinical effort, introducing the ADAPT framework























































































































